Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20880748 | 0.90 | ALDH1A1 (0.44) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL23937606 | 0.90 | ALDH1A1 (0.44) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL31668437 | 0.90 | LTA4H (0.44) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL23937492 | 0.90 | ALDH1A1 (0.44) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL30415091 | 0.86 | ALDH1A1 (0.46) | LTA4HSLC15A1ALDH1A1SLC1A3SLC1A1 | |
| SCHEMBL24328246 | 0.86 | SLC1A3 (0.41) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL561573 | 0.86 | LTA4H (0.56) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL124387 | 0.86 | LTA4H (0.56) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL21232385 | 0.86 | LTA4H (0.56) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 | |
| SCHEMBL28192478 | 0.86 | LTA4H (0.56) | LTA4HHTTSLC15A1ALDH1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | claimed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-20260070946-A1 | TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE | UNIV MIAMI (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559801-B2 | Compositions and methods for treating breast cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | disclosed |
| CN-110998328-B | Diagnosis and treatment of cancer | 拉布诊断公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025090760-A1 | ANTIBODIES SPECIFIC TO SCUBE3 AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | disclosed |
| US-11572630-B2 | Method and apparatus for water electrolysis, and method for determining drive potential of water electrolysis | RIKEN (JP) | 2023-02-07 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| US-11506668-B2 | Diagnosis and treatment of cancer | RAB DIAGNOSTICS AS (NO) | 2022-11-22 | — | — | US | disclosed |
| US-20220259674-A1 | COMPOSITIONS AND METHODS FOR TREATING BREAST CANCER | FRED HUTCHINSON CANCER CENTER | 2022-08-18 | — | — | US | disclosed |
| US-20220211864-A1 | ANTIBODY-DRUG CONJUGATES WITH IMMUNE-MEDIATED THERAPY AGENTS | MEDIMMUNE LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| EP-3998275-A1 | RECOMBINANT PEPTIDES THAT BIND TO A TUMOUR-SPECIFIC ANTIBODY FOR BREAST CANCER AND USE | Universidade Federal de Uberlândia (BR) | 2022-05-18 | — | — | EP | disclosed |
| US-11306326-B2 | Biologically active synthetic nanoparticle constructs and methods of use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-19 | — | — | US | disclosed |
| CN-114040996-A | Method and apparatus for electrolyzing water, and method for determining driving potential of electrolyzed water | 国立研究开发法人理化学研究所 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | ENGASE, MAN2B2, GALNT2 | LTA4H 3651/4885HTT 4087/4885SLC15A1 1474/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | LTA4H 3140/4885HTT 2868/4885SLC15A1 4788/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | LTA4H 3140/4885HTT 2868/4885SLC15A1 4788/4885 |
| US-20220211864-A1 | ANTIBODY-DRUG CONJUGATES WITH IMMUNE-MEDIATED THERAPY AGENTS | IGSF11, MCTS1, PAICS | LTA4H 2400/4885HTT 1994/4885SLC15A1 738/4885 |
| US-12559801-B2 | Compositions and methods for treating breast cancer | HSPA4L, EPB41L2, MELK | LTA4H 2749/4885HTT 4747/4885SLC15A1 1559/4885 |
| US-20260070946-A1 | TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE | XPNPEP1, PRAP1, YBX1 | LTA4H 4130/4885HTT 2773/4885SLC15A1 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.